Biomarkers for monitoring IgA nephropathy

Abstract

The present invention provides small RNA-based biomarkers for monitoring or detecting the pathogenesis and / or treatment process of IgA nephropathy, and the biomarkers are selected from the group consisting of miR-15a, miR-16, miR-21, miR-29a, miR-34a, miR-125b, miR-141, miR-148b, miR-155, miR-184, miR-192, miR-200a, miR-200b, miR-200c, miR-204, miR-205, miR-210 , miR-301a, and miR-429. The markerscan be used to well detect the course of treatment.

Description

technical field [0001] The invention belongs to the field of medical detection and relates to a biomarker for monitoring IgA nephropathy. Background technique [0002] IgA nephropathy (IgA nephropathy, IgAN) is the most common primary glomerulonephritis in the world. Although the prevalence of IgAN in the general population is low, its prevalence is high, especially in Asia, estimated at 30–40% in renal biopsies. Approximately 30-40% of IgAN patients will progress to end- (ERSD) within 20-30 years, making IgAN the leading cause of ERSD worldwide. However, the pathogenesis of IgAN remains unclear and available treatments only relieve symptoms and delay the need for dialysis and kidney transplantation. Among patients with IgAN, some respond well to treatment and maintain renal function for long periods of time, however, it is less understood that some patients are resistant to treatment and require dialysis more rapidly, and that mortality in IgAN patients is even higher tha...

AI Technical Summary

Problems solved by technology

Kidney biopsy is invasive and can lead to complications and is not suitable for monitoring disease progression

Images